- ►diabetesjournals.org V Fonseca, G Grunberger, S Gupta, S Shen, … - Diabetes Care, 2003 - Am Diabetes Assoc RESULTS—In placebo-treated patients, HbA 1c did not change (Δ = 0.0 ± 0.1%).
In patients randomized to nateglinide, HbA 1c decreased from 8.3 to 7.5% (Δ =
−0.8 ± 0.1%, P < 0.0001 vs. placebo). Target HbA 1c (<7.0%) was achieved ... Cited by 35 - Related articles - BL Direct - All 9 versions
ES Horton, JE Foley, SG Shen, MA Baron - Current Medical Research and Opinion®, 2004 - informahealthcare.com Objective: To assess the efficacy and tolerability of the combination of
nateglinide (120 mg, ac) and metformin (500 mg, tid) as initial treatment in
drug-naïve patients with type 2 diabetes mellitus (T2DM). Research design ... Cited by 19 - Related articles - BL Direct - All 7 versions
- ►diabetesjournals.org J Rosenstock, SG Shen, MR Gatlin, JE Foley - Diabetes Care, 2002 - Am Diabetes Assoc RESULTS—At the 16-week end point, nateglinide 120 mg, troglitazone 600 mg, and
the combination of the agents achieved statistically significant decreases in
HbA 1c in comparison with placebo and a baseline HbA 1c of 8.1–8.4% (P < ... Cited by 36 - Related articles - BL Direct - All 7 versions
- ►diabetesjournals.org P Raskin, L Klaff, J McGill, SA South, P … - Diabetes Care, 2003 - Am Diabetes Assoc RESULTS—Final HbA 1c values were lower for repaglinide/metformin treatment
than for nateglinide/metformin (7.1 vs. 7.5%). Repaglinide/metformin therapy
showed significantly greater mean reductions of HbA 1c (−1.28 vs. ... Cited by 46 - Related articles - BL Direct - All 7 versions
M Marre, L Van Gaal, KH Usadel, M Ball, I … - Diabetes Obesity and Metabolism, 2002 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 45 - Related articles - BL Direct - All 4 versions
- ►endojournals.org C Saloranta, K Hershon, M Ball, S Dickinson, … - Journal of Clinical Endocrinology & Metabolism, 2002 - Endocrine Soc Nateglinide is a fast-acting insulin secretion agent that specifically targets
postprandial hyperglycemia in patients with type 2 diabetes. The recent
reduction in the diagnostic criteria for diabetes and improved ... Cited by 43 - Related articles - BL Direct - All 6 versions
- Free from Publisher S Del Prato, RJ Heine, L Keilson, C Guitard … - Diabetes Care, 2003 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—Retrospective subgroup analyses were performed on
pooled data from all completed nateglinide studies (12 randomized, double blind
trials and 1 open trial) in patients with type 2 diabetes. A total of 3,702 ... Cited by 26 - Related articles - BL Direct - All 5 versions
- Free from Publisher P Phillips, J Karrasch, R Scott, D Wilson, R … - Diabetes Care, 2003 - Am Diabetes Assoc RESULTS—The intention-to-treat analysis from baseline to week 24 (81 patients
for HbA 1c and 82 for fasting blood glucose) showed statistically significant
differences between acarbose and placebo treatment in HbA 1c (1.02%; 95% CI ... Cited by 26 - Related articles - BL Direct - All 10 versions
Y Mori, G Kuriyama, N Tajima - Endocrine, 2004 - Springer Received August 26, 2004; Revised November 29, 2004; Accepted December 6, 2004.
Author to whom all correspondence and reprint requests should be addressed: Dr.
Yutaka Mori, Department of Internal Medicine, National Hospital ... Cited by 8 - Related articles - All 3 versions
- ►diabetesweb.de [PDF] - Free from Publisher PA Hollander, SL Schwartz, MR Gatlin, SJ … - Diabetes Care, 2001 - Am Diabetes Assoc RESULTS—During the liquid-meal challenge, nateglinide reduced the incremental
glucose area under the curve (AUC) more effectively than glyburide (Δ = −4.94
vs. −2.71 mmol · h/l, P < 0.05), whereas glyburide reduced fasting ... Cited by 100 - Related articles - BL Direct - All 7 versions
